Cargando…

Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas

Hashimoto’s thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT is a double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as a protective factor for PTC progr...

Descripción completa

Detalles Bibliográficos
Autores principales: Issa, Peter P., Omar, Mahmoud, Buti, Yusef, Issa, Chad P., Chabot, Bert, Carnabatu, Christopher J., Munshi, Ruhul, Hussein, Mohammad, Aboueisha, Mohamed, Shama, Mohamed, Corsetti, Ralph L., Toraih, Eman, Kandil, Emad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405831/
https://www.ncbi.nlm.nih.gov/pubmed/36009596
http://dx.doi.org/10.3390/biomedicines10082051
_version_ 1784773973693693952
author Issa, Peter P.
Omar, Mahmoud
Buti, Yusef
Issa, Chad P.
Chabot, Bert
Carnabatu, Christopher J.
Munshi, Ruhul
Hussein, Mohammad
Aboueisha, Mohamed
Shama, Mohamed
Corsetti, Ralph L.
Toraih, Eman
Kandil, Emad
author_facet Issa, Peter P.
Omar, Mahmoud
Buti, Yusef
Issa, Chad P.
Chabot, Bert
Carnabatu, Christopher J.
Munshi, Ruhul
Hussein, Mohammad
Aboueisha, Mohamed
Shama, Mohamed
Corsetti, Ralph L.
Toraih, Eman
Kandil, Emad
author_sort Issa, Peter P.
collection PubMed
description Hashimoto’s thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT is a double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as a protective factor for PTC progression. BRAF mutation in PTCs is associated with rapid cell growth, aggressive tumor characteristics, and higher mortality rates. Here, we aimed to analyze the influence of HT in patients with PTCs and its effect on lymph node metastasis (LNM) in BRAF mutant tumors. Adults diagnosed with PTC between 2008 and January 2021 were retrospectively included. A total of 427 patients, 128 of whom had underlying HT, were included. The HT group had significantly higher rates of microcarcinoma (49.2% vs. 37.5%, p = 0.025) and less lateral LNM (8.6% vs. 17.1%, p = 0.024). Interestingly, BRAF-mutated PTCs were found to have significantly less overall LNM (20.9% vs. 51%, p = 0.001), central LNM (25.6% vs. 45.1%, p = 0.040) and lateral LNM (9.3% vs. 29.4%, p = 0.010) in patients with HT when compared to those without underlying HT. HT was found to be an independent protective predictor of overall and lateral LNM. Altogether, HT was able to neutralize the effect of BRAF mutation and was determined to be an independent protective factor against LNM. Specifically, our work may influence treatment-aggressiveness decision making for endocrinologists, oncologists and surgeons alike.
format Online
Article
Text
id pubmed-9405831
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94058312022-08-26 Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas Issa, Peter P. Omar, Mahmoud Buti, Yusef Issa, Chad P. Chabot, Bert Carnabatu, Christopher J. Munshi, Ruhul Hussein, Mohammad Aboueisha, Mohamed Shama, Mohamed Corsetti, Ralph L. Toraih, Eman Kandil, Emad Biomedicines Article Hashimoto’s thyroiditis (HT) (autoimmune thyroiditis) is a clinicopathological entity associated with chronic lymphocytic infiltration resulting in hypothyroidism. HT is a double-edged sword that increases the risk of papillary thyroid cancer (PTC), yet it serves as a protective factor for PTC progression. BRAF mutation in PTCs is associated with rapid cell growth, aggressive tumor characteristics, and higher mortality rates. Here, we aimed to analyze the influence of HT in patients with PTCs and its effect on lymph node metastasis (LNM) in BRAF mutant tumors. Adults diagnosed with PTC between 2008 and January 2021 were retrospectively included. A total of 427 patients, 128 of whom had underlying HT, were included. The HT group had significantly higher rates of microcarcinoma (49.2% vs. 37.5%, p = 0.025) and less lateral LNM (8.6% vs. 17.1%, p = 0.024). Interestingly, BRAF-mutated PTCs were found to have significantly less overall LNM (20.9% vs. 51%, p = 0.001), central LNM (25.6% vs. 45.1%, p = 0.040) and lateral LNM (9.3% vs. 29.4%, p = 0.010) in patients with HT when compared to those without underlying HT. HT was found to be an independent protective predictor of overall and lateral LNM. Altogether, HT was able to neutralize the effect of BRAF mutation and was determined to be an independent protective factor against LNM. Specifically, our work may influence treatment-aggressiveness decision making for endocrinologists, oncologists and surgeons alike. MDPI 2022-08-22 /pmc/articles/PMC9405831/ /pubmed/36009596 http://dx.doi.org/10.3390/biomedicines10082051 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Issa, Peter P.
Omar, Mahmoud
Buti, Yusef
Issa, Chad P.
Chabot, Bert
Carnabatu, Christopher J.
Munshi, Ruhul
Hussein, Mohammad
Aboueisha, Mohamed
Shama, Mohamed
Corsetti, Ralph L.
Toraih, Eman
Kandil, Emad
Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title_full Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title_fullStr Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title_full_unstemmed Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title_short Hashimoto’s Thyroiditis Minimizes Lymph Node Metastasis in BRAF Mutant Papillary Thyroid Carcinomas
title_sort hashimoto’s thyroiditis minimizes lymph node metastasis in braf mutant papillary thyroid carcinomas
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405831/
https://www.ncbi.nlm.nih.gov/pubmed/36009596
http://dx.doi.org/10.3390/biomedicines10082051
work_keys_str_mv AT issapeterp hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT omarmahmoud hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT butiyusef hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT issachadp hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT chabotbert hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT carnabatuchristopherj hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT munshiruhul hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT husseinmohammad hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT aboueishamohamed hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT shamamohamed hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT corsettiralphl hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT toraiheman hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas
AT kandilemad hashimotosthyroiditisminimizeslymphnodemetastasisinbrafmutantpapillarythyroidcarcinomas